Cargando…

Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach

PARP-1 inhibition has been studied over the last decades for the treatment of various diseases. Despite the fact that several molecules act as PARP-1 inhibitors, a reduced number of compounds are used in clinical practice. To identify new compounds with a discriminatory PARP-1 inhibitory function, e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baptista, Salete J., Silva, Maria M. C., Moroni, Elisabetta, Meli, Massimiliano, Colombo, Giorgio, Dinis, Teresa C. P., Salvador, Jorge A. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266331/ https://www.ncbi.nlm.nih.gov/pubmed/28122037 http://dx.doi.org/10.1371/journal.pone.0170846

Ejemplares similares

Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors
por: Coimbra, Judite R. M., et al.
Publicado: (2020)

Dihydrofolate Reductase Inhibitors: The Pharmacophore as a Guide for Co-Crystal Screening
por: Baptista, João A., et al.
Publicado: (2021)

Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines
por: Gabano, Elisabetta, et al.
Publicado: (2021)

Molecular Dynamics Simulations of Hsp90 with an Eye to Inhibitor Design
por: Moroni, Elisabetta, et al.
Publicado: (2012)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)

Investigating the Dynamic Aspects of Drug-Protein Recognition through a Combination of MD and NMR Analyses: Implications for the Development of Protein-Protein Interaction Inhibitors
por: Meli, Massimiliano, et al.
Publicado: (2014)

A Hamiltonian Replica Exchange Molecular Dynamics (MD) Method for the Study of Folding, Based on the Analysis of the Stabilization Determinants of Proteins
por: Meli, Massimiliano, et al.
Publicado: (2013)

Dynamic and Multi-Pharmacophore Modeling for Designing Polo-Box Domain Inhibitors
por: Sakkiah, Sugunadevi, et al.
Publicado: (2014)

Search for the Pharmacophore of Histone Deacetylase Inhibitors Using Pharmacophore Query and Docking Study
por: Haji Agha Bozorgi, Atefeh, et al.
Publicado: (2014)

Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
por: Nizi, Maria Giulia, et al.
Publicado: (2023)

Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B
por: Masand, Vijay H., et al.
Publicado: (2022)

Are Amyloid Fibrils RNA-Traps? A Molecular Dynamics Perspective
por: Meli, Massimiliano, et al.
Publicado: (2018)

To disclose, or not to disclose? Context matters
por: Rahimzadeh, Vasiliki, et al.
Publicado: (2015)

Dynamic Diagnosis of Familial Prion Diseases Supports the β2-α2 Loop as a Universal Interference Target
por: Meli, Massimiliano, et al.
Publicado: (2011)

The Answer Lies in the Energy: How Simple Atomistic Molecular Dynamics Simulations May Hold the Key to Epitope Prediction on the Fully Glycosylated SARS-CoV-2 Spike Protein
por: Serapian, Stefano A., et al.
Publicado: (2020)

Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents
por: Dhuguru, Jyothi, et al.
Publicado: (2020)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Discovery of Potential M2 Channel Inhibitors Based on the Amantadine Scaffold via Virtual Screening and Pharmacophore Modeling
por: Tran, Linh, et al.
Publicado: (2011)

Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation for Identification of a Novel DNA Gyrase B Inhibitor with Benzoxazine Acetamide Scaffold
por: Elseginy, Samia A., et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Pharmacophore and Virtual Screening of JAK3 inhibitors
por: Rajeswari, Murugesan, et al.
Publicado: (2014)

Pharmacophoric Site Identification and Inhibitor Design for Autotaxin
por: Lee, Myeong Hwi, et al.
Publicado: (2019)

Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening
por: Goldmann, Daria, et al.
Publicado: (2015)

Novel Scaffolds for Modulation of NOD2 Identified by Pharmacophore-Based Virtual Screening
por: Guzelj, Samo, et al.
Publicado: (2022)

Recent advances in functionalized quinoline scaffolds and hybrids—Exceptional pharmacophore in therapeutic medicine
por: Elebiju, Oluwadunni F., et al.
Publicado: (2023)

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors
por: Zhou, Yunjiang, et al.
Publicado: (2019)

Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases
por: Kaserer, Teresa, et al.
Publicado: (2015)

Editorial: Computational drug discovery for targeting of protein-protein interfaces—Volume II
por: Morra, Giulia, et al.
Publicado: (2023)

Simple Model of Protein Energetics To Identify Ab Initio Folding Transitions from All-Atom MD Simulations of Proteins
por: Meli, Massimiliano, et al.
Publicado: (2020)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Towards a Pharmacophore for Amyloid
por: Landau, Meytal, et al.
Publicado: (2011)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

Chemical Synthesis, Efficacy, and Safety of Antimalarial Hybrid Drug Comprising of Sarcosine and Aniline Pharmacophores as Scaffolds
por: Niyibizi, Jean Baptiste, et al.
Publicado: (2020)

Propellanes as Rigid Scaffolds for the Stereodefined Attachment of σ-Pharmacophoric Structural Elements to Achieve σ Affinity
por: Torres-Gómez, Héctor, et al.
Publicado: (2021)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Pharmacophore elucidation and molecular docking studies on phosphodiesterase-5 inhibitors
por: Radwan, Awwad Abdoh
Publicado: (2015)

Why do children and adolescents with epilepsy disclose or not disclose their condition to their friends?
por: Jeschke, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9qcn3qd49bchgdbms8qone3nnq